Seek Pharmaceutical Breakthrough, New Policy to Deepen Medical Reform
On November 27, the State Council Information Office held a routine briefing on the policy, introducing relevant information on the recently released Several Policy Measures on Further Deepening Reform on Pharmaceutical Sanitary System with Central Drug Procurement and Use as Breakthrough. According to the meeting information, the imminent Several Policy Measures will put forward a portfolio of policy measures on reform on drug, medical care and insurance and enhancing regulation. With respect to medical reform, according to the Several Policy Measures, steadily and orderly advance joint reform of dynamic adjustment of medical service price. All places, in 2020-2022, should timely conduct yearly price regulation assessment according to the window period of trial on drug price cut and cancellation of mark-ups on consumables. When the conditions are met, timely conduct adjustment.
With respect to medical reform, Several Policy Measures puts forward six measures on important steps such as drug procurement, supply and quality. First, comprehensively deepen reform on central drug procurement and use, optimize central procurement mode and orderly expand drug variety scope. Second, establish the nationwide public drug procurement market and joint procurement pattern. For the drug not incorporated into the national procurement scope, all places rely on the provincial procurement platform to conduct central procurement. Third, actively advance generic drug quality and efficacy consistency evaluation, and speed up construction of drug information traceability system. Fourth, secure steady drug supply. Since the national central drug procurement, gradually establish the successful bidder emergency reserve, inventory and productivity report system. Fifth, encourage the medical insurance processing entity to directly settle the load with the production or distribution enterprise. Sixth, advance construction of national open and uniform drug production and circulation market pattern and speed up orderly market competitiveness.
Regarding medical reform, Several Policy Measures puts forward 3 measures, mainly emphasizing factors such as mobilizing medical institution’s initiative to use the selected drug, mobilizing reasonable clinical medical and establishing the new scientific operation mechanism. First, steadily and orderly advance joint reform on dynamic adjustment of medical service price, and conduct trial on optimizing medical service price without no general increase on the public burden. Second, forcefully advance remuneration system reform. All places are required to implement “two allowing” requirements, establish remuneration system and scientific and reasonable remuneration allocation system conforming to medical and sanitary characteristics, and implement autonomy assigned to public medical institutions. Third, strengthen management on standard medication of medical institution, promote medical institutions’ priority on dispensing and using national basic drug and drug in medical insurance category, and timely adjust and optimize the drug use catalog of medical institutions.
In order to speed up the establishment of an evidence system for the registration and evaluation of Chinese medicine which combines the traditional Chinese medicine (TCM) theory, human experience and clinical trial, standardize the writing of application documents for TCM theory and package inserts for TCM compound preparations of classic famous formula, under NMPA deployment, the Center for Drug Evaluation has coordinated formulation of the Guideline for Writing of Application Documents for Traditional Chinese Medicine (TCM) Theory of New TCM Compound Preparations (Trial) (Attachment 1), and the Guideline for Writing of Package Inserts for TCM Compound Preparations of Classic Famous Formula (Trial) (Attachment 2). In accordance with the Notice of Comprehensive Division, NMPA on Releasing the Technical Guideline for Pharmaceutical Products (YJZYG [2020] 9), after NMPA review and approval, it's hereby released and implemented since the date of release.
Noahpharm Presence in SAPA2021 China
Noahpharm Presence in SAPA2021 China
On October 14-15, 2021, hosted by Sino-American Pharmaceutical Professionals Association – China (SAPA-China), and guided and organized by the Management Committee of Suzhou High-tech Zone and the Management Committee of Suzhou Hushuguan Economy and Technology Development Zone, the Opportunity and Challenge for Chinese Biological Medicine Development and SAPA2021 China kicked off in Shishan International Convention Center in Suzhou High-tech Zone.
In golden autumn, Beijing Noahpharm Co. Ltd moved to a new address on October 11, 2021.The new office is situated in 3rd Floor, Building 11, Zone 4, Hanwei International Plaza, Fengtai Science and Technology Park, Beijing. The superior geological location and convenient transportation shorten our communication distance with customers, helping us meet customers’ demand in a better and faster way. The new location also facilitates employee mobility.
Provisions for the Supervision and Administration of Drug Production (No. 28 Order of the State Administration of Market Regulation, January 22, 2020)